Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT05703750

Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)

Conditions: Hepatocellular Carcinoma, Portal Hypertension

Sex: All

Ages: 18 Years – N/A

Enrollment: 228

Sponsor: Zhongda Hospital

Location: China

Summary

The purpose of this study is to discuss the prognostic value of CEPH among HCC patients underwent TACE treatment, its impact on overall survival, and try to stratify patient cohorts for a better treatment strategy.

Eligibility Criteria

Inclusion Criteria:Has a diagnosis of HCC confirmed by radiology, histology, or cytology;Received at least 1 TACE treatment；Exclusion Criteria:Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible;ECOG Performance Score > 2;History of spleen resection;Loss to follow-up.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05703750). StuddyBuddy aggregates publicly available trial information.